Stéphane Bancel

Stéphane joined Moderna in the summer of 2011 when it was a one employee company. He has assembled a world-class team and raised more than $1Billion between equity financing and upfront from licensing collaborations.

He was previously CEO of bioMérieux, a world leader in the diagnostics industry. bioMerieux has more than 6,000 employees, a market capitalization of €2.5 billion, and sales of more than €1.3 billion.

Prior to his time at bioMérieux, Stéphane was the managing director of Eli Lilly Belgium and executive director of global manufacturing strategy and supply chain at Eli Lilly in Indianapolis, Indiana. He started at Lilly in their UK manufacturing plant outside London.

He holds a Master of Engineering from École Central Paris, a Master of Science in Chemical Engineering from the University of Minnesota and an MBA from Harvard Business School.

Stéphane was elected a 2009 Young Global Leader by the World Economic Forum. He was elected best CEO for investor relations in France in 2009 and was ranked the number one CEO in the biotech sector according to the 2011 Thomson Reuters EXTEL Study. Stéphane serves as a supervisory director of Qiagen N.V., and on the Board of Directors of Syros Pharmaceuticals.